and have announced the progression of a SIRPα inhibitor antibody, BI 770371, to clinical trial. The cancer immunology treatment will enter a Phase Ib trial. The advancement is part of a broader immuno-oncology programme aimed at enhancing the body’s immune response to cancer cells.
The gold standard of business intelligence. SIRPα is a receptor on macrophages that, when bound to a cluster of differentiation 47 (CD47), inhibits the immune system’s ability to destroy cancer cells. By blocking SIRPα, the new antibody aims to promote the destruction of cancer cells by macrophages.
Boehringer Ingelheim translational medicine and clinical pharmacology global head Vittoria Zinzalla stated: “We are very excited about progressing the SIRPα program which was initiated by OSE. “With the positive data from our first clinical studies and the switch to an improved antibody, we hope to achieve our aim of accelerating and expanding our pipeline of first-in-class cancer therapies to transform the lives of patients affected by cancer.” Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form OSE, focusing on the immuno-oncology and immuno-inflammatio.
